Skip to main content
Print Save

Generic Upneeq Availability

Last updated on Jan 11, 2023.

Upneeq is a brand name of oxymetazoline ophthalmic, approved by the FDA in the following formulation(s):

UPNEEQ (oxymetazoline hydrochloride - solution/drops;ophthalmic)

  • Manufacturer: RVL PHARMS
    Approval date: July 8, 2020
    Strength(s): 0.1% [RLD]

Has a generic version of Upneeq been approved?

No. There is currently no therapeutically equivalent version of Upneeq available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Upneeq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,799,481

    Patent expiration dates:

    • December 16, 2039
      ✓ 
      Patent use: METHOD OF TREATING BLEPHAROPTOSIS
  • Patent 10,814,001

    Patent expiration dates:

    • December 16, 2039
      ✓ 
      Drug product
  • Patent 10,898,573

    Patent expiration dates:

    • December 16, 2039
      ✓ 
      Drug product
  • Patent 10,912,765

    Patent expiration dates:

    • August 26, 2031
      ✓ 
      Patent use: METHOD OF TREATING BLEPHAROPTOSIS
  • Patent 10,940,138

    Patent expiration dates:

    • December 16, 2039
      ✓ 
      Patent use: METHOD OF TREATING BLEPHAROPTOSIS
  • Patent 11,103,482

    Patent expiration dates:

    • December 16, 2039
      ✓ 
      Drug product
  • Patent 11,311,515

    Patent expiration dates:

    • December 16, 2039
      ✓ 
      Drug product
  • Patent 11,324,722

    Patent expiration dates:

    • December 16, 2039
      ✓ 
      Patent use: METHOD OF TREATING BLEPHAROPTOSIS
  • Patent 11,541,036

    Patent expiration dates:

    • December 16, 2039
      ✓ 
      Drug product
  • Compositions and methods for non-surgical treatment of ptosis
    Patent 8,357,714
    Issued: January 22, 2013
    Assignee(s): Voom, LLC

    Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

    Patent expiration dates:

    • August 26, 2031
      ✓ 
      Patent use: METHOD OF TREATING BLEPHAROPTOSIS
  • Compositions and methods for non-surgical treatment of Ptosis
    Patent 9,867,808
    Issued: January 16, 2018
    Assignee(s): VOOM, LLC

    Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

    Patent expiration dates:

    • August 26, 2031
      ✓ 
      Patent use: METHOD OF TREATING BLEPHAROPTOSIS

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • July 8, 2023 - NEW PRODUCT

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer